A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Sapacitabine (Primary) ; Seliciclib (Primary)
  • Indications Breast cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 28 Mar 2017 According to a Cyclacel Pharmaceuticals media release, company is enrolling BRCA positive patients with advanced breast cancer in extension part of this trial. Part 3 of this trial has been initiated.
    • 10 Aug 2016 According to a Cyclacel Pharmaceuticals media release, the company plnas to add part 3 to include BRCA mutation positive, pancreatic and ovarian cancer patients.
    • 07 Jun 2016 Results from part 1 and 2 (n=67) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top